HARBIN, China, May 14 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,
Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading
fully integrated pharmaceutical company in the People's Republic of China
("PRC"), today announced that Mr. Yan-Qing Liu, the Company's Chairman and
Chief Executive Officer, received the award for "Leadership Excellence in
Innovation" from the organizing committee of China Enterprise Innovation Forum.
Mr. Liu will attend the 10th China Enterprise Innovation Forum and the award ceremony held in Beijing on June 6, 2010. The Enterprise Innovation Forum is sponsored by a number of industry associations, including the Chinese Association for Productivity & Science, which was established under the approval of China's Ministry of Civil Affairs in 1980. There will be over 500 attendees including senior government officials, economists, business leaders as well as journalists. Each year in China, this award is presented to up to 50 business leaders who have demonstrated leadership in driving innovation at their companies and generating considerable economic benefits.
"I accept this honor on behalf of all the employees at China Sky One Medical who have helped to drive the Company's innovative advances over the years. We will continue our focus on developing and commercializing novel medical technologies and drugs to help physicians and patients, and create long term value for our shareholders," said Mr. Liu.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include the innovation activities and its effect on the Company's operational results. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the ability to develop new technologies and products, market acceptance of new product launches, achievability of management's estimates of product sales, the effect of changing economic conditions in The People's Republic of China, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
Advertisement
Mr. Liu will attend the 10th China Enterprise Innovation Forum and the award ceremony held in Beijing on June 6, 2010. The Enterprise Innovation Forum is sponsored by a number of industry associations, including the Chinese Association for Productivity & Science, which was established under the approval of China's Ministry of Civil Affairs in 1980. There will be over 500 attendees including senior government officials, economists, business leaders as well as journalists. Each year in China, this award is presented to up to 50 business leaders who have demonstrated leadership in driving innovation at their companies and generating considerable economic benefits.
Advertisement
"I accept this honor on behalf of all the employees at China Sky One Medical who have helped to drive the Company's innovative advances over the years. We will continue our focus on developing and commercializing novel medical technologies and drugs to help physicians and patients, and create long term value for our shareholders," said Mr. Liu.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include the innovation activities and its effect on the Company's operational results. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the ability to develop new technologies and products, market acceptance of new product launches, achievability of management's estimates of product sales, the effect of changing economic conditions in The People's Republic of China, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
Company Contact:
China Sky One Medical, Inc.
Mr. Stanley Hao, CFO
Tel: +86-0451-87032617
Email: [email protected]
Investor Relations Contact:
CCG Investor Relations
Ms. Lei Huang, Account Manager
Tel: +1-646-833-3417
Email: [email protected]
Website: http://www.ccgirasia.com
Ms. Mabel Zhang, Vice President
Tel: +1-310-954-1353
Email: [email protected]
SOURCE China Sky One Medical, Inc.